LP04 : A phase 3, open-label, single-arm study to evaluate the efficacy and safety of 12 weeks of simeprevir (SMV) plus sofosbuvir (SOF) in treatment-naïve or -experienced patients with chronic HCV genotype 1 infection and cirrhosis: Optimist-2

Publication | Open Access

DOI Full Paper Access

Citations

References

2015

Year

Eric Lawitz, Gary Matusow, E DeJesus, Eric M. Yoshida, Franco Felizarta, Reem Ghalib, Eliot Godofsky, Robert Herring, Gary D. Poleynard, Aasim Sheikh,

Journal of Hepatology

Single-arm StudyHepatologyHepatitis C-Experienced PatientsViral HepatitisAntiviral TherapyHepatitisVirologyChronic Viral InfectionAntiviral DrugMedicineEpidemiologyPhase 3